Celltrion, maker of biosimilar infliximab CT-P13 (Remsima, Inflectra), has recently submitted an application to the European Medicines Agency for a subcutaneous formulation of the biosimilar.
Celltrion, maker of biosimilar infliximab CT-P13 (Remsima, Inflectra), has recently submitted an application to the European Medicines Agency for a subcutaneous formulation of the biosimilar.
Previous research has established that the proposed subcutaneous formulation of CT-P13 has similar safety and efficacy to the intravenous CT-P13 up to week 30 in patients with Crohn disease (CD) and rheumatoid arthritis. A new study sought to report the pharmacokinetics (PK), efficacy, and safety of the subcutaneous formulation in patients with CD up to 1 year of treatment.1
The study enrolled 44 patients who were assigned to 1 of 4 cohorts. The first cohort received weight-based intravenous therapy, whereas the second, third, and fourth cohorts received fixed doses of 120 mg, 180 mg, and 240 mg, respectively, of the subcutaneous CT-P13 formulation every 2 weeks up to week 54.
Overall, clinical response results were comparable between the cohorts after randomization at week 6 and up to week 30. Clinical remission was numerically higher in the subcutaneous-therapy cohorts at week 54. The mean predose serum concentration of CT-P13 before next dose injection was higher in the subcutaneous-therapy cohorts than in the intravenous-therapy cohort throughout the study after randomization; these values increased with the dose of the subcutaneous product and were substantially higher than the target therapeutic concentration.
Safety profiles were comparable across cohorts, and, in total, 11.4% of patients reported injection-site reactions (ISRs), all of which were grade 1 or 2.
The researchers concluded that these results suggest similar efficacy and safety of intravenous and subcutaneous CT-P13 and that the novel formulation “may expand treatment options for use of infliximab biosimilar by providing high consistency in drug exposure during maintenance treatment.”
A second study of the biosimilar focused on evaluating the PK and overall safety of the subcutaneous formulation as administered by autoinjector versus prefilled syringe.2
A total of 218 healthy volunteers were randomized to receive a single 120-mg dose of the subcutaneous CT-P13 via autoinjector or prefilled syringe. At week 12, PK and safety were assessed.
Overall, the mean serum concentration of CT-P13 following a single dose showed a similar trend throughout the study period in both arms, and safety results were comparable between arms. The proportion of individuals who experienced ISRs was lower in the autoinjector group than in the prefilled syringe group, as was the mean of injection site pain.
The proportion of patients who developed antidrug antibodies was similar between arms.
According to the authors, these results demonstrate equivalent PK and comparable safety of the subcutaneous CT-P13 in healthy volunteers treated with either of the 2 administration options.
References
1. Reinisch W, Jang BI, Borzan V, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomised controlled trial in patients with active Crohn’s disease. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract DOP62. ecco-ibd.eu/publications/congress-abstract-s/abstracts-2019/item/dop62-a-novel-formulation-of-ct-p13-infliximab-biosimilar-for-subcutaneous-administration-1-year-result-from-a-phase-i-open-label-randomised-controlled-trial-in-patients-with-active-crohn-8217-s-disease.html.
2. Schreiber S, Ben-Horin S, Ye BD, et al. Development of a novel auto-injector of subcutaneous CT-P13 infliximab: phase 1 randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P679. ecco-ibd.eu/publications/congress-abstract-s/item/p679-development-of-a-novel-auto-injector-of-subcutaneous-ct-p13-infliximab-phase-i-randomised-open-label-single-dose-trial-to-compare-the-pharmacokinetics-and-safety-to-pre-filled-syringe-in-healthy-subjects.html.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.